ConforMIS has filed to raise up to $172.5 million through an initial public offering of common shares, according to a Health Point Capital report.
Here are four things to know:
1. The company intends to use the funds to expand the company's manufacturing capacity, sales, research and development, clinical activities as well as to fund working capital.
2. ConforMIS develops customized joint replacement implants through its proprietary iFit Image-to-Implant technology platform. It currently offers knee implants, but is planning to submit an application for approval of its iTotal Hip, a customized hip implant.
3. Since 2004, ConforMIS has raised an aggregate of $330 million from the sale of preferred stock and the exercise of preferred stock warrants and common stock warrants and options.
4. JP Morgan and Deutsche Bank are acting as joint lead book runners on the deal.